Therapeutic Indications

Bevacizumab is indicated for:

Epithelial ovarian, fallopian tube and primary peritoneal cancer

No gender/age discrimination

Bevacizumab, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Bevacizumab, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.

Bevacizumab in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 15mg/kg of body weight given once every 3 weeks

Cervical Cancer

No gender/age discrimination

Bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 15mg/kg of body weight given once every 3 weeks

Advanced and/or metastatic renal cell cancer (mRCC)

No gender/age discrimination

Bevacizumab in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 10 mg/kg of body weight given once every 2 weeks

Metastatic breast cancer (mBC) - First-line treatment

Irrespective of gender only Adults (18 years old or older)

Bevacizumab in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer.

Bevacizumab in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline-containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with bevacizumab in combination with capecitabine.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 10 mg/kg of body weight once every 2 weeks

Treatment 2: Intravenous - 15 mg/kg of body weight once every 3 weeks

Metastatic carcinoma of the colon or rectum (mCRC)

Irrespective of gender only Adults (18 years old or older)

Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 5-10 mg/kg of body weight given once every 2 weeks

Treatment 2: Intravenous - 7.5-15 mg/kg of body weight given once every 3 weeks

Non-small cell lung cancer (NSCLC) - First-line treatment

Irrespective of gender only Adults (18 years old or older)

Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 7.5-15 mg/kg of body weight once every 3 weeks

Contraindications

Active ingredient Bevacizumab is contraindicated in the following cases:

Pregnancy

No gender/age discrimination

There are no data on the use of bevacizumab in pregnant women. Studies in animals have shown reproductive toxicity including malformations bevacizumab. IgGs are known to cross the placenta, and bevacizumab is anticipated to inhibit angiogenesis in the foetus, and thus is suspected to cause serious birth defects when administered during pregnancy. Bevacizumab is contraindicated in pregnancy.